Literature DB >> 10674283

Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism.

J J Fahrenfort1, A M Wilterdink, E A van der Veen.   

Abstract

The issue of residual complaints after treatment for hyperthyroidism in current euthyroid patients was investigated by means of a survey. Patients treated for hyperthyroidism were selected from medical records of the previous 6 years in two Dutch University Clinics. After the exclusion of patients with comorbidity, 303 one-time hyperthyroid respondents were included in the analysis. A total of 77% of these patients had been diagnosed with Graves' Disease. The newly developed Hyperthyroidism Complaint Questionnaire (HCQ), was used to quantify problems of somatic and mental functioning. The SymptomsCheckList-90 (SCL-90) was used to assess self-reported psychopathological symptoms, the Nottingham Health Profile was used to measure perceived health/quality of life. Dysthyroid patients (n = 20) had a mean HCQ-score of 14.5 (+/- 8.1) complaints; patients who reported euthyroidism for less than 12 months (n = 171) had a mean of 9.3 (+/- 7.6) residual complaints; patients who reported euthyroidism for more than 12 months (n = 54) a mean of 6.6 (+/- 6.8) residual complaints. On each dimension of psychopathology covered by the SCL-90, including depression and anxiety, approximately one third of the total sample had a score exceeding 80% of adult females. According to the NHP lack of energy was evident in 53% of all respondents. Over one third of patients with a full-time job were unable to resume the same work after treatment. It appears that many of these patients are in need of psychological support.

Entities:  

Mesh:

Year:  2000        PMID: 10674283     DOI: 10.1016/s0306-4530(99)00050-5

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  29 in total

Review 1.  Psychiatric manifestations of Graves' hyperthyroidism: pathophysiology and treatment options.

Authors:  Robertas Bunevicius; Arthur J Prange
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 2.  Anxiety and medical disorders.

Authors:  Jacqueline E Muller; Liezl Koen; Dan J Stein
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

3.  Desensitization and Incomplete Recovery of Hepatic Target Genes After Chronic Thyroid Hormone Treatment and Withdrawal in Male Adult Mice.

Authors:  Kenji Ohba; Melvin Khee-Shing Leow; Brijesh Kumar Singh; Rohit Anthony Sinha; Ronny Lesmana; Xiao-Hui Liao; Sujoy Ghosh; Samuel Refetoff; Judy Chia Ghee Sng; Paul Michael Yen
Journal:  Endocrinology       Date:  2016-02-11       Impact factor: 4.736

4.  Neuroanatomic Variations in Graves' Dysthyroid Ophthalmopathy as Studied With MRI.

Authors:  Rona Z Silkiss; Alex R Wade
Journal:  Trans Am Ophthalmol Soc       Date:  2017-05-24

5.  Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment.

Authors:  Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson
Journal:  Thyroid       Date:  2019-05-13       Impact factor: 6.568

6.  Thyroid and Cardiovascular Disease Research Agenda for Enhancing Knowledge, Prevention, and Treatment.

Authors:  Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson
Journal:  Circulation       Date:  2019-05-13       Impact factor: 29.690

7.  Reversible changes in brain glucose metabolism following thyroid function normalization in hyperthyroidism.

Authors:  Q Miao; S Zhang; Y H Guan; H Y Ye; Z Y Zhang; Q Y Zhang; R D Xue; M F Zeng; C T Zuo; Y M Li
Journal:  AJNR Am J Neuroradiol       Date:  2011-05-19       Impact factor: 3.825

8.  Thyroid hormone status and health-related quality of life in the LifeLines Cohort Study.

Authors:  Elise I Klaver; Hannah C M van Loon; Riejanne Stienstra; Thera P Links; Joost C Keers; Ido P Kema; Anneke C Muller Kobold; Melanie M van der Klauw; Bruce H R Wolffenbuttel
Journal:  Thyroid       Date:  2013-09       Impact factor: 6.568

9.  Establishing construct validity for the thyroid-specific patient reported outcome measure (ThyPRO): an initial examination.

Authors:  Torquil Watt; Jakob Bue Bjorner; Mogens Groenvold; Ase Krogh Rasmussen; Steen Joop Bonnema; Laszlo Hegedüs; Ulla Feldt-Rasmussen
Journal:  Qual Life Res       Date:  2009-03-14       Impact factor: 4.147

10.  Improving a newly developed patient-reported outcome for thyroid patients, using cognitive interviewing.

Authors:  Torquil Watt; Ase Krogh Rasmussen; Mogens Groenvold; Jakob Bue Bjorner; Sara Hope Watt; Steen Joop Bonnema; Laszlo Hegedüs; Ulla Feldt-Rasmussen
Journal:  Qual Life Res       Date:  2008-06-27       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.